← Back to Search

Hormone Therapy

DHEA + Exercise for Osteoporosis

N/A
Waitlist Available
Led By Julio Carballido-Gamio, PhD
Research Sponsored by University of Colorado, Denver
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 36 weeks
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing whether a hormone called DHEA and specific exercises can help improve bone strength in older women with bone loss. The study will look at how these treatments affect bone marrow fat, which is important for bone health. The goal is to find new ways to prevent fractures and improve treatment for osteoporosis. DHEA has been studied for its potential benefits in bone health, including increasing bone mineral density and promoting osteoblast activity.

Who is the study for?
Postmenopausal women aged 55-85 with low bone mass or moderate osteoporosis, not currently doing high impact exercise more than twice a week, willing to do a 36-week exercise program and take DHEA or placebo. Must have completed COVID vaccination, no severe health issues like uncontrolled diabetes, recent cancer treatment (except skin cancer), heart disease, or metal implants if participating in MRI study.
What is being tested?
The trial is testing the effects of the hormone DHEA and an exercise program on bone marrow fat among older women with bone loss. The goal is to understand how these interventions could improve bone strength by affecting the microenvironment within bones over a period of 36 weeks.
What are the potential side effects?
Potential side effects from taking DHEA may include oily skin, acne, hair loss, stomach upset, high blood pressure changes in menstrual cycle for those who are not fully menopausal. Exercise might cause muscle soreness or injury if not done properly.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~36 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 36 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Changes in hip bone marrow fat content
Changes in spine bone marrow fat content
Correlation of hip bone marrow fat content with hip strength at baseline
+3 more
Other study objectives
spatial distribution of the changes in bone marrow fat content of the hip
spatial distribution of the changes in bone marrow fat content of the spine

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

4Treatment groups
Experimental Treatment
Group I: no exercise and placeboExperimental Treatment2 Interventions
no supervised bone-loading exercise and one placebo pill per day for 36 weeks
Group II: no exercise and DHEAExperimental Treatment2 Interventions
no supervised bone exercise and one dose of DHEA (50 milligrams) per day for 36 weeks
Group III: Exercise and placeboExperimental Treatment2 Interventions
supervised bone-loading exercise 3 days per week and one placebo pill per day for 36 weeks
Group IV: Exercise and DHEAExperimental Treatment2 Interventions
supervised bone-loading exercise 3 days per week and one dose of DHEA (50 milligrams) per day for 36 weeks
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
DHEA
2004
Completed Phase 4
~2300
Exercise
2016
Completed Phase 1
~820

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Dehydroepiandrosterone (DHEA) acts as a hormonal precursor for estrogens and androgens, which are crucial for bone health. DHEA promotes osteoblast differentiation and increases bone mineral density (BMD) by up-regulating osteoblast-related genes and enhancing the activity of Foxp3(+) regulatory T cells. Bone-loading exercises, on the other hand, provide mechanical stimulation that enhances bone formation and increases BMD by promoting the activity of osteoblasts. These mechanisms are vital for osteoporosis patients as they help improve bone strength, reduce the risk of fractures, and counteract the bone loss associated with the condition.
Whole-body vibration exercise in postmenopausal osteoporosis.DHEA promotes osteoblast differentiation by regulating the expression of osteoblast-related genes and Foxp3(+) regulatory T cells.Dehydroepiandrosterone administration increased trabecular mass and dihydrotestosterone levels in the cancellous region of the tibia in young female rats.

Find a Location

Who is running the clinical trial?

University of Colorado, DenverLead Sponsor
1,809 Previous Clinical Trials
2,822,258 Total Patients Enrolled
11 Trials studying Osteoporosis
1,085 Patients Enrolled for Osteoporosis
Julio Carballido-Gamio, PhDPrincipal InvestigatorUniversity of Colorado, Denver
Catherine Jankowski, PhDPrincipal InvestigatorUniversity of Colorado, Denver
3 Previous Clinical Trials
189 Total Patients Enrolled
2 Trials studying Osteoporosis
186 Patients Enrolled for Osteoporosis

Media Library

DHEA (Hormone Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT05316272 — N/A
DHEA (Hormone Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05316272 — N/A
~11 spots leftby Dec 2025